[Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies].
OBJECTIVE
To evaluate the efficacy and toxicity of topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies.


METHODS
Twenty-one patients with refractory or relapsed acute leukemia (AL), non-Hodgkin's lymphoma (NHL) or high risk myelodysplastic syndrome (MDS) were treated by topotecan with cytarabine, amsacrine or cyclophosphamide. All patients received a single course as salvage therapy.


RESULTS
The overall response rate of one course was 61.9% with 9/21 (42.9%) CR and 4/21 (19%) PR. Severe myelosuppression was observed in all patients. Agranulocytic time was 12.6 days in AL and 7.5 days in NHL. Sixteen of 21 patients received G-CSF 300 micro g/d All patients received supportive treatment of transfusion. Fever and documented infection developed in 15 patients. Non-hematologic toxicity was mild.


CONCLUSIONS
Topotecan-based combined chemotherapy has significant antitumour activity and acceptable toxicity as salvage therapy for high risk hematologic malignancies.
Wu
De-pei
DP
Department of Hematology, First Hospital of Suzhou University, Jiangsu Institute of Hematology, Suzhou 215006, China.
Tang
Xiao-wen
XW
Sun
Ai-ning
AN
Qiu
Hui-ying
HY
Fu
Zheng-zheng
ZZ
Ma
Rao
R
Ruan
Chang-geng
CG
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002648:Child; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019772:Topotecan / Q000008:administration & dosage* / Q000009:adverse effects
D019772:Topotecan